{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:05:25Z","timestamp":1694934325608},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Economy and Competitiveness (MINECO)","award":["SAF2012-31613","RD12\/0036\/0061"],"award-info":[{"award-number":["SAF2012-31613","RD12\/0036\/0061"]}]},{"name":"Comunidad de Madrid\/European Union","award":["S2010\/BMD-2314-Neoplasbim"],"award-info":[{"award-number":["S2010\/BMD-2314-Neoplasbim"]}]},{"name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital Universitario Puerta de Hierro"},{"name":"Roche Pharma"},{"name":"IAJ","award":["JAEPre2010-00607"],"award-info":[{"award-number":["JAEPre2010-00607"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.bbrc.2015.04.007","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T19:40:09Z","timestamp":1428781209000},"page":"243-248","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways"],"prefix":"10.1016","volume":"461","author":[{"given":"Carol","family":"Lozano-Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Amigo-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Nova-Gurumeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"P\u00e9rez-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles","family":"Garc\u00eda-Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Garc\u00eda-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2015.04.007_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrclinonc.2009.72","article-title":"Molecular and cellular mechanisms of CLL: novel therapeutic approaches","volume":"6","author":"Pleyer","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2015.04.007_bib3","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2013-05-498287","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"122","author":"Hallek","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.04.007_bib4","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-14-1889","article-title":"New strategies in chronic lymphocytic leukemia: shifting treatment paradigms","volume":"20","author":"Awan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2015.04.007_bib5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/phar.1509","article-title":"Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia","volume":"34","author":"Chung","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbrc.2015.04.007_bib6","first-page":"44","article-title":"A\u00a0review of arsenic trioxide and acute promyelocytic leukemia","volume":"8","author":"Alimoghaddam","year":"2014","journal-title":"Int. J. Hematol. Oncol. Stem Cell. Res."},{"key":"10.1016\/j.bbrc.2015.04.007_bib7","first-page":"1018","article-title":"Arsenic trioxide for non acute promyelocytic leukemia hematological malignancies: a new Frontier","volume":"1","author":"Zhou","year":"2014","journal-title":"J.\u00a0Blood Dis."},{"key":"10.1016\/j.bbrc.2015.04.007_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12029-014-9617-8","article-title":"In the war against solid tumors arsenic trioxide needs partners","volume":"45","author":"Subbarayan","year":"2014","journal-title":"J.\u00a0Gastrointest. Cancer"},{"key":"10.1016\/j.bbrc.2015.04.007_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00109-008-0314-6","article-title":"Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13","volume":"86","author":"Merkel","year":"2008","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.bbrc.2015.04.007_bib10","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/1078-0432.CCR-10-0072","article-title":"Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the PI3K\/Akt pathway via JNK activation and PTEN upregulation","volume":"16","author":"Redondo-Mu\u00f1oz","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2015.04.007_bib11","doi-asserted-by":"crossref","first-page":"e99993","DOI":"10.1371\/journal.pone.0099993","article-title":"Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide","volume":"9","author":"Amigo-Jim\u00e9nez","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2015.04.007_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes","volume":"85","author":"Roecklein","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.04.007_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.bbrc.2015.04.007_bib14","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.04.007_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.12344","article-title":"Chronic lymphocytic leukaemia\u2013the role of the microenvironment pathogenesis and therapy","volume":"162","author":"Ramsay","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib18","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2015.04.007_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3324\/haematol.10703","article-title":"Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"92","author":"Ishitsuka","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2015.04.007_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1535-7163.MCT-06-0349","article-title":"Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells","volume":"6","author":"Park","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2015.04.007_bib21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","article-title":"Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase C\u03b4","volume":"21","author":"Yan","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2015.04.007_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/1871520611009060504","article-title":"Combination therapy with arsenic trioxide for hematological malignancies","volume":"10","author":"Takahashi","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2015.04.007_bib23","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","article-title":"Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes","volume":"32","author":"Efficace","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bjc.2014.374","article-title":"Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a transition to targeted therapies","volume":"112","author":"Arteaga","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2015.04.007_bib25","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1182\/blood-2004-07-2802","article-title":"Pharmacologic inhibitors of PI3K\/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells","volume":"105","author":"Ramos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.04.007_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jcp.20153","article-title":"Phosphoinositide 3-kinase\/Akt involvement in arsenic trioxide resistance of human leukemia cells","volume":"202","author":"Tabellini","year":"2005","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib27","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2006-12-060970","article-title":"Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway","volume":"110","author":"Bornhauser","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2015.04.007_bib28","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.bcp.2012.09.022","article-title":"2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt\/mTOR, MEK\/ERK and LKB-1\/AMPK signaling pathways","volume":"84","author":"Esta\u00f1o","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2015.04.007_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.leukres.2010.03.011","article-title":"The role of Bcl-2 family proteins in chronic lymphocytic leukaemia","volume":"34","author":"Buggins","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbrc.2015.04.007_bib30","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neo.2014.10.002","article-title":"Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia","volume":"16","author":"Balakrishnan","year":"2014","journal-title":"Neoplasia"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15006737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15006737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:01:36Z","timestamp":1598904096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15006737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0006291X15006737"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.04.007","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}